SCHEMBL30691598

SCHEMBL30691598

CC(C)(C)OC(=O)NC1CCC=C(C(=O)O)C1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.48
▸ KDM1A O60341 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ CTSK P43235 2/20 0.45
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ NFKB1 P19838 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42
▸ RELA Q04206 1/20 0.42
▸ KCNA3 P22001 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ CKS1B P61024 1/20 0.41
▸ SKP1 P63208 1/20 0.41
▸ SKP2 Q13309 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ DRD2 P14416 2/20 0.38
▸ EPHX1 P07099 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15233218 0.85 BTK (0.47) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL15559191 0.85 BTK (0.47) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL2633760 0.85 BTK (0.47) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL26462792 0.85 CTSK (0.42) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL6644209 0.78 CES2 (0.50) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL12519778 0.78 CES2 (0.50) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL25608426 0.78 NFKB1 (0.44) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL14820714 0.78 CTSK (0.50) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL23048922 0.77 KDM1A (0.45) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL470791 0.76 BTK (0.53) BTKKDM1AMAOBCTSKKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4543444-A1 COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 PTC Therapeutics, Inc. (US) 2025-04-30 — — EP disclosed
WO-2023250316-A1 COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 PTC THERAPEUTICS, INC. (US) 2023-12-28 — — WO disclosed
Send feedback